Products with Anti-aging bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5625 | Verminoside |
| 1. Verminoside exhibits anti-inflammatory, anti-bacterial and anti-properties. 2. Verminoside induces genotoxicity on human lymphocytes, involved with PARP-1 and p53 proteins. 3. Verminoside shows significant anti-inflammatory effects, can inhibit both iNOS expression and NO release in the LPS-induced J774.A1 macrophage cell line. 4. Verminoside attenuates intracellular ROS and stress (oxidative and thermal) level promoting longevity, the longevity and stress modulation can be attributed to VMS-mediated alterations in daf-16 expression which regulates insulin signaling pathway. | |
| BCN5738 | Paeonol |
| Paeonol has anticancer, anti-inflammatory, antioxidant and cardiovascular protective activities, it shows a novel inhibitory role on neuroinflammation, and presents a new candidate agent for the development of therapies for inflammation-related neurodegenerative diseases. Paeonol suppresses lipopolysaccharide-induced inflammatory cytokines in macrophage cells and protects mice from lethal endotoxin shock. Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively; it inhibits PGE₂ synthesis and COX-2 expression, and modulates Sirtuin 1, PKCδ and c-Src signaling pathway. | |
| BCN5980 | Lipoic acid |
| Alpha-lipoic acid has become a common ingredient in multivitamin formulas, anti-aging supplements, and even pet food, it is well-defined as a therapy for preventing diabetic polyneuropathies, and scavenges free radicals, chelates metals, and restores intracellular glutathione levels which otherwise decline with age. Alpha-lipoic acid has therapeutic effects on joint inflammation and erosion in an animal model via NF-kappa B down regulation, it inhibits TNF-alpha induced NF-kappa B activation through blocking of MEKK1-MKK4-IKK signaling cascades. Lipoic acid is a novel treatment for Alzheimer's disease and related dementias. | |
| BCN6049 | Quercetin |
| Quercetin is one of the most prominent dietary antioxidants, it is claimed to exert beneficial health effects, this includes protection against various diseases such as osteoporosis, certain forms of cancer, pulmonary and cardiovascular diseases but also against aging. It is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4±0.6 μM, 3.0±0.0 μM and 5.4±0.3 μM for PI3K γ, PI3K δ and PI3K β, respectively. It also attenuated the function VEGFR, androgen receptor and the expressions of NF-κB, IL Receptor, FAK, ERK,Nrf2. | |
| BCN6295 | Cyclogalegigenin |
| 1. Cycloastragenol and astragaloside IV can suppress ROS-associated ER stress and then inhibit TXNIP/NLRP3 inflammasome activation with regulation of AMPK activity, and thereby ameliorate endothelial dysfunction by inhibiting inflammation and reducing cell apoptosis. 2. Cycloastragenol stimulates telomerase activity in human neonatal keratinocytes and rat neuronal cells, and induces CREB activation followed by tert and bcl2 expression, cycloastragenol may have a novel therapeutic role in depression. 3. Cycloastragenol can suppress the accumulation of cytoplasmic lipid droplet in 3T3-L1 adipocytes. 4. Cycloastragenol and astragaloside IV have been shown to improve the proliferative response of CD8+ T lymphocytes from HIV-infected patients by upregulating telomerase activity, they also may exert their cellular effects through the activation of the Src/MEK/ERK pathway. 5. Cycloastragenol can remarkably inhibit CYP3A4 and activate CYP2E1 in rats. 6. Cycloastragenol has been shown to extend T cell proliferation by increasing telomarase activity showing that it may also help delay the onset of cellular aging; it is an extraordinary wound healing agent; it inhibits the apoptosis of PC12 induced by 6-OHDA, may be as potential neuroprotective agents in the treatment of Parkinson's disease. | |
